

## Author Index Volume 3 (2014)

The issue number is given in front of the pagination

- Adams, W.H., see Beglinger, L.J. (2) 139-144  
Aerts, A.M., see Lee, J.H. (1) 65-71  
Aikin, A.M., see Corey-Bloom, J. (3) 311-316  
Alosio, W., see Farrar, A.M. (2) 145-158  
Altemus, M., see A. Wolfram-Aduan (4) 387-399  
Anderson, K.E., V. Divino, M. DeKoven, D. Langbehn, J.H. Warner, J. Giuliano and W.C. Lee, Interventional Differences Among Huntington's Disease Patients by Disease Progression in Commercial and Medicaid Populations (4) 355-363  
Aronin, N., see Vodicka, P. (2) 159-174  
  
Baddeley, R.J., see Metzler-Baddeley, C. (3) 273-283  
Barclay, J.E., see Hennig, B.L. (4) 351-353  
Beck, C.A., see Bull, M.T. (2) 189-195  
Beconi, M., see Vodicka, P. (2) 159-174  
Beglinger, L.J., W.H. Adams, D. Langbehn, J.G. Fiedorowicz, J. Caviness, K. Biglan, B. Olson and J.S. Paulsen, Does Interval Between Screening and Baseline Matter in HD Cognitive Clinical Trials? (2) 139-144  
Beste, C., see Ness, V. (1) 33-43  
Bestgen, A.-K., see Ness, V. (1) 33-43  
Bezprozvanny, I., see Liang, X. (4) 343-350  
Biglan, K., see Beglinger, L.J. (2) 139-144  
Biglan, K.M., see Bull, M.T. (2) 189-195  
Birch, H., see Vodicka, P. (2) 159-174  
Bird, T., see Davis, M.Y. (2) 209-217  
Björkqvist, M., see Magnusson-Lind, A. (1) 13-24  
Blakemore, C., see Mazarakis, N.K. (3) 299-309  
Booij, S.J., A. Tibben, D.P. Engberts and R.A.C. Roos, Perhaps the subject of the questionnaire was too sensitive: Do we expect too much too soon? (3) 229-232  
Borchelt, D.R. and C.A. Ross, Gabriele Schilling (September 5, 1968—July 4, 2014) (3) 225-227  
Borchelt, D.R., see Tebbenkamp, A.T.N. (1) 73-86  
Boudreau, R.L., see Lee, J.H. (1) 65-71  
Bowles, K.R. and L. Jones, Kinase Signalling in Huntington's Disease (2) 89-123  
Brown, A., see Fisher, C.A. (4) 319-332  
Brown, H.H., see Tebbenkamp, A.T.N. (1) 73-86  
Brunner, D., see Farrar, A.M. (2) 145-158  
Bull, M.T., K. Darwin, V. Venkataraman, J. Wagner, C.A. Beck, E.R. Dorsey and K.M. Biglan, A Pilot Study of Virtual Visits in Huntington Disease (2) 189-195  
Buonincontri, G., N.I. Wood, S.G. Puttick, A.O. Ward, T.A. Carpenter, S.J. Sawiak and A.J. Morton, Right Ventricular Dysfunction in the R6/2 Transgenic Mouse Model of Huntington's Disease is Unmasked by Dobutamine (1) 25-32  
Buren, C., L. Wang, A. Smith-Dijak and L.A. Raymond, Region-specific Pro-survival Signaling and Global Neuronal Protection by Wild-type Huntingtin (4) 365-376  
Busse, M., L. Quinn, H. Khalil, K. McEwan and the Outcome Measures Subgroup of the European Huntington's Disease Network, Optimising Mobility Outcome Measures in Huntington's Disease (2) 175-188  
  
Cantera, J., see Metzler-Baddeley, C. (3) 273-283  
Carlozzi, N.E., A. Miciura, N. Migliore and P. Dayalu, Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review (3) 233-252  
Carpenter, T.A., see Buonincontri, G. (1) 25-32  
Caviness, J., see Beglinger, L.J. (2) 139-144  
Chase, K., see Vodicka, P. (2) 159-174  
Churchyard, A., see Fisher, C.A. (4) 319-332  
Coleman, A., see Jones, R. (2) 197-207  
Corey-Bloom, J., H. Jia, A.M. Aikin and E.A. Thomas, Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease (3) 311-316  
Coulthard, E., see Metzler-Baddeley, C. (3) 273-283  
Craufurd, D., see Sitek, E.J. (2) 125-135  
  
Darwin, K., see Bull, M.T. (2) 189-195  
Davidson, B.L., see Lee, J.H. (1) 65-71  
Davidsson, M., see Magnusson-Lind, A. (1) 13-24  
Davis, M.Y., C.D. Keene, S. Jayadev and T. Bird, The Co-Occurrence of Alzheimer's Disease and

- Huntington's Disease: A Neuropathological Study of 15 Elderly Huntington's Disease Subjects (2) 209-217
- Dayalu, P., see Carlozzi, N.E. (3) 233-252
- Deacon, R., see Mazarakis, N.K. (3) 299-309
- DeKoven, M., see Anderson, K.E. (4) 355-363
- DiFiglia, M., see Vodicka, P. (2) 159-174
- Divino, V., see Anderson, K.E. (4) 355-363
- Dominguez, C., see Vodicka, P. (2) 159-174
- Dorsey, E.R., see Bull, M.T. (2) 189-195
- Dumas, E.M., see Jones, R. (2) 197-207
- Dumas, E.M., see van den Bogaard, S.J.A. (4) 377-386
- Durr, A., see Jones, R. (2) 197-207
- Egorova, P., see Liang, X. (4) 343-350
- Engberts, D.P., see Booij, S.J. (3) 229-232
- Farrar, A.M., C.A. Murphy, N.E. Paterson, S. Oakeshott, D. He, W. Alosio, K. McConnell, L.B. Menalled, S. Ramboz, L.C. Park, D. Howland and D. Brunner, Cognitive Deficits in Transgenic and Knock-in *HTT* Mice Parallel those in Huntington's Disease (2) 145-158
- Faull, R.L.M., see Nana, A.L. (1) 45-64
- Fiedorowicz, J.G., see Beglinger, L.J. (2) 139-144
- Fisher, C.A., K. Sewell, A. Brown and A. Churchyard, Aggression in Huntington's Disease: A Systematic Review of Rates of Aggression and Treatment Methods (4) 319-332
- Fromholt, S.E., see Tebbenkamp, A.T.N. (1) 73-86
- Frost, C., see Jones, R. (2) 197-207
- Gertsberg, A.G., see Hennig, B.L. (4) 351-353
- Giuliano, J., see Anderson, K.E. (4) 355-363
- Gusella, J.F., see Thompson, M.N. (3) 261-271
- Hannan, A.J., see Mazarakis, N.K. (3) 299-309
- Hansen, C., see Magnusson-Lind, A. (1) 13-24
- Hart, E., see Jones, R. (2) 197-207
- He, D., see Farrar, A.M. (2) 145-158
- Hennig, B.L., R.F. Kaplan, A.E. Nowicki, J.E. Barclay and A.G. Gertsberg, We Can Predict When Driving is No Longer Safe for People Who Have HD Using Standard Neuropsychological Measures (4) 351-353
- Hill della Puppa, G., see Miller, S. (4) 333-341
- Hogg, V.M., see Nana, A.L. (1) 45-64
- Hou, J., see Liang, Y. (3) 253-259
- Howland, D., see Farrar, A.M. (2) 145-158
- Janus, C., see Tebbenkamp, A.T.N. (1) 73-86
- Jayadev, S., see Davis, M.Y. (2) 209-217
- Jia, H., see Corey-Bloom, J. (3) 311-316
- Jones, D.K., see Metzler-Baddeley, C. (3) 273-283
- Jones, L., see Bowles, K.R. (2) 89-123
- Jones, R., J.C. Stout, I. Labuschagne, M. Say, D. Justo, A. Coleman, E.M. Dumas, E. Hart, G. Owen, A. Durr, B.R. Leavitt, R. Roos, A. O'Regan, D. Langbehn, S.J. Tabrizi and C. Frost, The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease (2) 197-207
- Justo, D., see Jones, R. (2) 197-207
- Kan, H.E., see van den Bogaard, S.J.A. (4) 377-386
- Kaplan, R.F., see Hennig, B.L. (4) 351-353
- Keene, C.D., see Davis, M.Y. (2) 209-217
- Kegel, K.B., see Vodicka, P. (2) 159-174
- Khalil, H., see Busse, M. (2) 175-188
- Kim, E.H., see Nana, A.L. (1) 45-64
- Klamer, D., see Waters, S. (3) 285-298
- Labuschagne, I., see Jones, R. (2) 197-207
- Langbehn, D., see Anderson, K.E. (4) 355-363
- Langbehn, D., see Beglinger, L.J. (2) 139-144
- Langbehn, D., see Jones, R. (2) 197-207
- Leavitt, B.R., see Jones, R. (2) 197-207
- Leavitt, B.R., see Plecash, A.R. (1) 5-11
- Lee, J.H., M.J. Sowada, R.L. Boudreau, A.M. Aerts, D.R. Thedens, P. Nopoulos and B.L. Davidson, Rhes Suppression Enhances Disease Phenotypes in Huntington's Disease Mice (1) 65-71
- Lee, W.C., see Anderson, K.E. (4) 355-363
- Liang, X., J. Wu, P. Egorova and I. Bezprozvanny, An Automated and Quantitative Method to Evaluate Progression of Striatal Pathology in Huntington's Disease Transgenic Mice (4) 343-350
- Liang, Y., Y. Yao, M. Lu, J. Hou, S. Yu and B. Lu, TR-FRET Assays for Endogenous Huntingtin Protein Level in Mouse Cells (3) 253-259
- Lim, J., see Vodicka, P. (2) 159-174
- Lu, B., see Liang, Y. (3) 253-259
- Lu, M., see Liang, Y. (3) 253-259
- Lyons, K., see Vodicka, P. (2) 159-174
- MacDonald, M.E., see Thompson, M.N. (3) 261-271
- Magnusson-Lind, A., M. Davidsson, E. Silajdžić, C. Hansen, A.C. McCourt, S.J. Tabrizi and M. Björkqvist, Skeletal Muscle Atrophy in R6/2 Mice – Altered Circulating Skeletal Muscle Markers and Gene Expression Profile Changes (1) 13-24
- Marchionini, D., see Vodicka, P. (2) 159-174
- Marcora, E., see Miller, S. (4) 333-341

- Margolis, R.L., Tetrabenazine, Depression and Suicide: Good News (2) 137-138
- Mazarakis, N.K., C. Mo, T. Renoir, A. van Dellen, R. Deacon, C. Blakemore and A.J. Hannan, 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease (3) 299-309
- McConnell, K., see Farrar, A.M. (2) 145-158
- McCourt, A.C., see Magnusson-Lind, A. (1) 13-24
- McEwan, K., see Busse, M. (2) 175-188
- Mead, T., see Vodicka, P. (2) 159-174
- Menalled, L.B., see Farrar, A.M. (2) 145-158
- Metzler-Baddeley, C., J. Cantera, E. Coulthard, A. Rosser, D.K. Jones and R.J. Baddeley, Improved Executive Function and Callosal White Matter Microstructure after Rhythm Exercise in Huntington's Disease (3) 273-283
- Miciura, A., see Carlozzi, N.E. (3) 233-252
- Migliore, N., see Carlozzi, N.E. (3) 233-252
- Miller, S., G. Hill della Puppa, J. Reidling, E. Marcora, L.M. Thompson and J. Treanor, Comparison of Phosphodiesterase 10A, Dopamine Receptors D1 and D2 and Dopamine Transporter Ligand Binding in the Striatum of the R6/2 and BACHD Mouse Models of Huntington's Disease (4) 333-341
- Mo, C., see Mazarakis, N.K. (3) 299-309
- Morton, A.J., see Buonincontri, G. (1) 25-32
- Murphy, C.A., see Farrar, A.M. (2) 145-158
- Myre, M.A., see Thompson, M.N. (3) 261-271
- Nana, A.L., E.H. Kim, D.C.V. Thu, D.E. Oorschot, L.J. Tippett, V.M. Hogg, B.J. Synek, R. Roxburgh, H.J. Waldvogel and R.L.M. Faull, Widespread Heterogeneous Neuronal Loss Across the Cerebral Cortex in Huntington's Disease (1) 45-64
- Ness, V., A.-K. Bestgen, C. Saft and C. Beste, Changes in Cognitive Control in Pre-Manifest Huntington's Disease Examined Using Pre-Saccadic EEG Potentials – A Longitudinal Study (1) 33-43
- Nopoulos, P., see Lee, J.H. (1) 65-71
- Nowicki, A.E., see Hennig, B.L. (4) 351-353
- O'Regan, A., see Jones, R. (2) 197-207
- Oakeshott, S., see Farrar, A.M. (2) 145-158
- Olson, B., see Beglinger, L.J. (2) 139-144
- Oorschot, D.E., see Nana, A.L. (1) 45-64
- Owen, G., see Jones, R. (2) 197-207
- Park, H., see Vodicka, P. (2) 159-174
- Park, L.C., see Farrar, A.M. (2) 145-158
- Paterson, N.E., see Farrar, A.M. (2) 145-158
- Paulsen, J.S., see Beglinger, L.J. (2) 139-144
- Plecash, A.R. and B.R. Leavitt, Aquatherapy for Neurodegenerative Disorders (1) 5-11
- Ponten, H., see Waters, S. (3) 285-298
- Puttick, S.G., see Buonincontri, G. (1) 25-32
- Quinn, L., see Busse, M. (2) 175-188
- Ramboz, S., see Farrar, A.M. (2) 145-158
- Raymond, L.A., see Buren, C. (4) 365-376
- Reidling, J., see Miller, S. (4) 333-341
- Renoir, T., see Mazarakis, N.K. (3) 299-309
- Roos, R., see Jones, R. (2) 197-207
- Roos, R.A.C., see Booij, S.J. (3) 229-232
- Roos, R.A.C., see van den Bogaard, S.J.A. (4) 377-386
- Ross, C.A., see Borchelt, D.R. (3) 225-227
- Rosser, A., see Metzler-Baddeley, C. (3) 273-283
- Roxburgh, R., see Nana, A.L. (1) 45-64
- Saft, C., see Ness, V. (1) 33-43
- Sandstrom, M.I., see A. Wolfram-Aduan (4) 387-399
- Sawiak, S.J., see Buonincontri, G. (1) 25-32
- Say, M., see Jones, R. (2) 197-207
- Sewell, K., see Fisher, C.A. (4) 319-332
- Siemienski, Z.B., see Tebbenkamp, A.T.N. (1) 73-86
- Silajdžić, E., see Magnusson-Lind, A. (1) 13-24
- Sitek, E.J., J.C. Thompson, D. Craufurd and J.S. Snowden, Unawareness of Deficits in Huntington's Disease (2) 125-135
- Smith-Dijk, A., see Buren, C. (4) 365-376
- Snowden, J.S., see Sitek, E.J. (2) 125-135
- Southwell, A.L. and N.S. Wexler, Paul H. Patterson (October 22, 1943—June 25, 2014) (3) 221-224
- Sowada, M.J., see Lee, J.H. (1) 65-71
- Stout, J.C., see Jones, R. (2) 197-207
- Swing, D., see Tebbenkamp, A.T.N. (1) 73-86
- Synek, B.J., see Nana, A.L. (1) 45-64
- Tabrizi, S.J., see Jones, R. (2) 197-207
- Tabrizi, S.J., see Magnusson-Lind, A. (1) 13-24
- Tebbenkamp, A.T.N., G. Xu, Z.B. Siemienski, C. Janus, S.E. Fromholt, H.H. Brown, D. Swing, L. Tessarollo and D.R. Borchelt, Experimental Mutagenesis of Huntingtin to Map Cleavage Sites: Different Outcomes in Cell and Mouse Models (1) 73-86
- Teeuwisse, W.M., see van den Bogaard, S.J.A. (4) 377-386
- Tessarollo, L., see Tebbenkamp, A.T.N. (1) 73-86

- Thepens, D.R., see Lee, J.H. (1) 65-71  
Thomas, E.A., see Corey-Bloom, J. (3) 311-316  
Thompson, J.C., see Sitek, E.J. (2) 125-135  
Thompson, L.M., see Miller, S. (4) 333-341  
Thompson, M.N., M.E. MacDonald, J.F. Gusella and M.A. Myre, Huntingtin Supplies a csaA-Independent Function Essential for EDTA-Resistant Homotypic Cell Adhesion in *Dictyostelium discoideum* (3) 261-271  
Thu, D.C.V., see Nana, A.L. (1) 45-64  
Tibben, A., see Booij, S.J. (3) 229-232  
Tippett, L.J., see Nana, A.L. (1) 45-64  
Treasor, J., see Miller, S. (4) 333-341
- van Buchem, M.A., see van den Bogaard, S.J.A. (4) 377-386  
van Dellen, A., see Mazarakis, N.K. (3) 299-309  
van den Bogaard, S.J.A., E.M. Dumas, W.M. Teeuwisse, H.E. Kan, A. Webb, M.A. van Buchem, R.A.C. Roos and J. van der Grond, Longitudinal Metabolite Changes in Huntington's Disease During Disease Onset (4) 377-386  
van der Grond, J., see van den Bogaard, S.J.A. (4) 377-386  
Venkataraman, V., see Bull, M.T. (2) 189-195  
Vodicka, P., J. Lim, D.T. Williams, K.B. Kegel, K. Chase, H. Park, D. Marchionini, S. Wilkinson, T. Mead, H. Birch, D. Yates, K. Lyons, C. Dominguez, M. Beconi, Z. Yue, N. Aronin and M. DiFiglia, Assessment of Chloroquine Treatment for Modulating Autophagy Flux in Brain of WT and HD Mice (2) 159-174  
Wagner, J., see Bull, M.T. (2) 189-195  
Waldvogel, H.J., see Nana, A.L. (1) 45-64  
Wang, L., see Buren, C. (4) 365-376  
Ward, A.O., see Buonincontri, G. (1) 25-32  
Warner, J.H., see Anderson, K.E. (4) 355-363  
Waters, N., see Waters, S. (3) 285-298  
Waters, S., H. Ponten, D. Klamer and N. Waters, Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats (3) 285-298  
Webb, A., see van den Bogaard, S.J.A. (4) 377-386  
Wexler, A., Huntington's Disease in Popular Culture: A Brief Historical Perspective (1) 1-4  
Wexler, N.S., see Southwell, A.L. (3) 221-224  
Wickwire, J.H., see A. Wolfram-Aduan (4) 387-399  
Wilkinson, S., see Vodicka, P. (2) 159-174  
Williams, D.T., see Vodicka, P. (2) 159-174  
Wolfram-Aduan, A., M. Altemus, J.H. Wickwire and M.I. Sandstrom, Presymptomatic Glutamate Levels in Prefrontal Cortex in the Hdh<sup>(CAG150)</sup> Mouse Model of Huntington's Disease (4) 387-399  
Wolfram-Aduan, A., see A. Wolfram-Aduan (4) 387-399  
Wood, N.I., see Buonincontri, G. (1) 25-32  
Wu, J., see Liang, X. (4) 343-350  
Xu, G., see Tebbenkamp, A.T.N. (1) 73-86  
Yao, Y., see Liang, Y. (3) 253-259  
Yates, D., see Vodicka, P. (2) 159-174  
Yu, S., see Liang, Y. (3) 253-259  
Yue, Z., see Vodicka, P. (2) 159-174